Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.

ABSTRACT: SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine (CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes.Eligibility: histologically proven LAPC ?7?cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles: GEM 1000?mg?m-2 days 1, 8, 15; CAP 830?mg?m-2 days 1-21 q28 days) patients with stable/responding disease, tumour ?6?cm, and WHO Performance Status 0-1 were randomised to receive one cycle GEMCAP followed by CAP (830?mg?m-2 b.d. on weekdays only) or GEM (300?mg?m-2 weekly) with radiation (50.4?Gy per 28 fractions).One-hundred fourteen patients (28 UK centres) were registered between 24 December 2009 and 25 October 2011, and 74 were randomised (CAP-RT=36; GEM-RT=38). At the time of this analysis, 105 of the 114 patients had died and the surviving 9 patients had been followed up for a median of 10.9 months (IQR: 2.9-18.7). Updated median OS was 17.6 months (95% CI: 14.6-22.7) in the CAP-CRT arm and 14.6 months (95% CI: 11.1-16.0) in the GEM-CRT arm (intention-to-treat adjusted hazard ratio (HR): 0.68 (95% CI: 0.38-1.21, P=0.185)); median progression-free survival (PFS) was 12.0 months (95% CI: 10.0-15.2) in the CAP-CRT arm and 10.4 months (95% CI: 8.8-12.7) in the GEM-CRT arm (intention-to-treat adjusted HR: 0.60 (95% CI: 0.32-1.14, P=0.120)). In baseline multivariable model, age ?65 years, better performance status, CA19.9<613?IU?l-1, and shorter tumour diameter predicted improved OS. CAP-CRT, age ?65 years, better performance status, CA19.9 <46?IU?ml-1 predicted improved OS and PFS in the pre-radiotherapy model. Nine-month PFS was highly predictive of OS.CAP-CRT remains the superior regimen. SCALOP showed that patients with CA19.9 <46?IU?ml-1 after induction chemotherapy are more likely to benefit from CRT.

SUBMITTER: Hurt CN 

PROVIDER: S-EPMC5482737 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature